ClinicalTrials.gg
CompletedNCT01208922ERASEUpdated Feb 27, 2019Results posted

Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea

A Phase 3 interventional study of Rifamycin SV-MMX® and Ciprofloxacin in Traveler's Diarrhea, sponsored by Dr. Falk Pharma GmbH. Completed at 19 sites in 3 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-02-27.

Sponsored by Dr. Falk Pharma GmbH · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
835
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 42 studies in Diarrhea with a site in India — none open to participants now, 1 under way, none of them phase 3. Diarrhea · India.

Enrollment
21st of 40
835 · median 918
Started
2010
with 4 others
Phase 3
9 of 42
none open now
Registered
22nd of 42
by date

Among the 42 studies in Diarrhea with a site in India, this one is the 21st largest by enrollment of the 40 interventional ones that give a count, is one of 5 that started in 2010, is one of 9 in phase 3, and was the 22nd registered.

Diarrhea

880 studies on the registry are indexed under Diarrhea; 78 are open to participants now.

Browse Diarrhea studies →

Open to participants now

None of the 42 studies in Diarrhea with a site in India is open now. The open studies under Diarrhea, anywhere →

Who these studies take

Of the 45 Diarrhea studies recruiting now, 21 (47%) set no upper age limit and 22 (49%) stop at 75 or younger; 19 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 42 studies in Diarrhea with a site in India as a file.
02

Study summary

The purpose of this study is to prove the non-inferiority of Rifamycin SV-MMX® versus Ciprofloxacin for the treatment of adults with traveller's diarrhoea.

03

Conditions studied

  • Traveler's Diarrhea

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed ,
  • Men or women between 18 and 85 years of age,
  • History of arriving from their country of residence in the industrialized part of the world within the past 4 weeks,
  • Presenting with acute infectious diarrhoea (defined as at least 3 unformed, watery or soft stools accompanied by symptoms within 24 hours preceding randomisation with duration of illness ≤ 72 hours),
  • Presence of one or more signs or symptoms of enteric infection (moderate to severe gas/flatulence, nausea, vomiting, abdominal cramps or pain, rectal tenesmus, fecal urgency),
  • Women of had to apply during the entire duration of the study a highly effective method of

Exclusion criteria

Exclusion Criteria:

  • Residency in any country with high incidence rate of TD within the past 6 months,
  • Fever (defined as a body (oral) temperature >100.4°F or 38.0°C; antipyretic medication should not have been administered in the 6 hours prior to this assessment),
  • Known or suspected infection with non-bacterial pathogen,
  • Presence of diarrhoea of >72 hours duration,
  • Presence of grossly bloody stool,
  • Presence of moderate or severe dehydration (i.e. symptoms of hypovolemia such as orthostatic hypotension, dizziness or wrinkling of skin),
  • History of inflammatory bowel disease or celiac disease,
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
835 participants (actual)

Study arms

  • Experimental
    Group A

    Rifamycin SV-MMX® 200 mg tablets

    Drug: Rifamycin SV-MMX®

  • Active comparator
    Group B

    Ciprofloxacin 500 mg capsules

    Drug: Ciprofloxacin

Interventions

  • DrugRifamycin SV-MMX®

    2 Rifamycin SV-MMX® 200 mg tablets and 1 placebo to ciprofloxacin capsule, b.i.d.

  • 1 ciprofloxacin 500 mg capsule and 2 placebos to Rifamycin SV-MMX® 200 mg tablets, b.i.d.

06

What researchers measure

Primary outcomes

  1. Time to Last Unformed Stool (TLUS)

    Time to Last Unformed Stool (TLUS), defined as the interval in hours between the first dose of study drug and the last unformed stool passed, after which clinical cure was declared.

    Time frame: 5 days

Secondary outcomes

  1. Number of Patients With Clinical Cure

    Clinical Cure Rate: 24-hour period with no clinical symptoms except mild flatulence, no fever, no watery stools and no more than 2 soft stools OR 48-hour period with no stools or only formed stools, and no fever, with our without symptoms of enteric infection.

    Time frame: 5 days

07

Results

Posted Feb 27, 2019

Participant flow

Recruited from November 2010 until January 2016

Participant flow — Overall Study
MilestoneRifamycin GroupCiprofloxacin Group
Started420415
Completed409405
Not completed1110

Outcome measures

PrimaryTime to Last Unformed Stool (TLUS)

Time to Last Unformed Stool (TLUS), defined as the interval in hours between the first dose of study drug and the last unformed stool passed, after which clinical cure was declared.

Time frame:
5 days
Reported as:
Median · hours
Time to Last Unformed Stool (TLUS)
hoursGroup AGroup B
Time to Last Unformed Stool (TLUS)44.3 (40.1 to 47.5)40.3 (33.5 to 44.8)
SecondaryNumber of Patients With Clinical Cure

Clinical Cure Rate: 24-hour period with no clinical symptoms except mild flatulence, no fever, no watery stools and no more than 2 soft stools OR 48-hour period with no stools or only formed stools, and no fever, with our without symptoms of enteric infection.

Time frame:
5 days
Reported as:
Count of participants · Participants
Number of Patients With Clinical Cure
ParticipantsGroup AGroup B
Number of Patients With Clinical Cure357352

Adverse events

Collected over An average of 1 month. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A0/420 (0%)0/420 (0%)36/420 (8.6%)
Group B0/415 (0%)0/415 (0%)32/415 (7.7%)
Most frequent other events
Most frequent other events
EventGroup AGroup B
HeadacheNervous system disorders13/4209/415
DiarrhoeaGastrointestinal disorders8/4206/415
NauseaGastrointestinal disorders6/4206/415
FlatulenceGastrointestinal disorders5/4206/415
Abdominal painGastrointestinal disorders4/4205/415

Baseline characteristics

Baseline results were reported for Full Analysis Set, which included all randomised patients (as randomised) who received at least one dose of study medication. Patients with uncertainty as to whether they had received study medication or not (e.g., due to lost to follow-up) were included.

Age, Continuous
Age, Continuous(years)Group AGroup BTotal
Mean40.0 ± 16.140.4 ± 16.640.2 ± 16.3
Sex: Female, Male
Sex: Female, Male(Participants)Group AGroup BTotal
Female215197412
Male205218423
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group AGroup BTotal
American Indian or Alaska Native000
Asian7568143
Native Hawaiian or Other Pacific Islander000
Black or African American011
White342344686
More than one race000
Unknown or Not Reported325
Region of Enrollment
Region of Enrollment(participants)Group AGroup BTotal
Ecuador101
Guatemala141529
India405400805
08

Study locations

19 sites
  • Site 401
    Quito, Ecuador
  • Site 200
    Quetzaltenango, Guatemala
  • Site 101
    Mapusa, Karaswada, India
  • Site 124
    Ajmer, India
  • Site 118
    Bardez, India
  • Site 120
    Calangute, India
  • Site 104
    Hyderabad, India
  • Site 114
    Kolkata, India
  • Site 116
    Lucknow, India
  • Site 107
    Margao, India
  • Site 110
    Margao, India
  • Site 123
    New Delhi, India
  • Site 122
    Panaji, India
  • Site 102
    Pondichéry, India
  • Site 115
    Pushkar, India
  • Site 119
    Salcette, India
  • Site 111
    Tiswadi, India
  • Site 109
    Varanasi, India
  • Site 103
    Vijayawada, India
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Jan 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2019, 3 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2010
First posted
Sep 24, 2010
Start
Nov 2010
Primary completionActual
Jan 2016
CompletionActual
May 2016
Results first posted
Feb 27, 2019
Last update
Feb 27, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01208922
Responsible party
Sponsor
First posted
Sep 24, 2010
Start date
Nov 2010
Primary completion
Jan 2016
Completion
May 2016
Results posted
Feb 27, 2019
Last update
Feb 27, 2019

Study contacts

Professor Robert Steffen, M. D.
principal investigator · University of Zurich, Switzerland

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion